Targeting T cell populations, particularly those expected to provide protection from viral infection, has been met with little enthusiasm in the context of other T cell-mediated conditions. Long-term T cell depletion with anti-CD52 proved to be associated with relatively little morbidity in trials for rheumatoid disease, but a
more subtle approach targeting T cell signalling probably remains a more attractive option, perhaps through the JAK/STAT pathway.
- more subtle approach T cell signalling JAK/STAT pathway = JAK-STAT inhibitors
Can anyone speak to the horribility or otherwise of JAK-STAT inhibitors?
As a side-question, why do these drugs all seem to need to be infused/injected? Google isn't very helpful on this. Presumably they'd all get wrecked by stomach acid but what is it about them, as opposed to, say, aspirin, that makes them wreckable?